Citations

Showing 10 of 107969 citations.

High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Zayac, Adam , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie E , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Evens, Andrew M. , Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Rubinstein, P , Chaudhry, Amina, Epperla, Narendranath , Zayac, Adam S , Bock, Allison M , Ayers, Emily C , Girton, Mark , Hu, Marie , Li, Shaoying , Medeiros, L Jeffrey , Chang, Julie E , Torka, Pallawi , Smith, Stephen D , Karimi, Yasmin H , Bond, David A , Naik, Seema G , Haverkos, Bradley M , Karmali, Reem , Farooq, Umar , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Evens, Andrew M , Naresh, Kikkeri N , Kamdar, Manali , Epperla, Narendranath , Landsburg, Daniel J. , Medeiros, L. Jeffrey , Kurt, Habibe , Sundaram, Suchitra , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | August 27, 2024 | Volume: 8 | Issue: 20 | Pages: 5355-5364

10.1182/bloodadvances.2024013791 | PMID 39189932 Get It

Abstract Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal = 6, parenchymal = 4, and both = 1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR = 3.5) and testicular (in men) or female pelvic (in women) involvement (OR = 8.1). There was no significant difference in survival outcomes between patients with HGBL NOS with (median PFS = 4 years) or without (median PFS = 2.4 years) baseline CNS involvement (P = 0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% vs 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non–germinal center B-cell subtype, and “dual-expresser lymphoma” phenotype, however, high CNS IPI was not. The prognosis of relapsed HGBL NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and chimeric antigen receptor T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease.
Case 332
Adler, Cameron , Menias, Christine O. , Menias, Christine Cooky O , Adler, Cameron R

Mayo Clinic

Radiology | August 27, 2024 | Volume: 312 | Issue: 2 | Pages: No page available

10.1148/radiol.232149 | PMID 39189900 Get It

History A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrectomy developed recurrent disease adjacent to the inferior vena cava. The patient underwent surveillance imaging 7 months after initiation of treatment with maximum-dose pazopanib and less than 1 month after completing a 2-month regimen of palliative stereotactic body radiation therapy to the right nephrectomy bed and site of recurrence. (Stereotactic body radiation therapy was initiated 5 months after pazopanib treatment was initiated.) One month after initiating treatment with pazopanib and 6 months before the surveillance imaging, the patient developed diarrhea and required ongoing treatment with loperamide to control symptoms. He denied any fatigue, mouth sores, or extremity pain, but described some abdominal pain and discomfort associated with the diarrhea. He was not experiencing any fevers, and vital signs were normal. White blood cell count was normal at 5100/μL (5.1 ×109/L) (normal range, 4200–10 200/μL [4.2–10.2 ×109/L]), with all components of the differential count also being normal. A normal serum albumin level of 3.9 g/dL (39 g/L) (normal range, 3.5–5.0 g/dL [35–50 g/L]) and low serum total protein level of 6.1 g/dL (61 g/L) (normal range, 6.3–7.9 g/dL [63–79 g/L]) were noted. A comprehensive metabolic panel was performed, indicating a serum chloride level of 98 mmol/L (normal, 100–108 mmol/L) and alkaline phosphatase level of 121 U/L (2.02 μkat/L) (normal, 45–115 U/L [0.75–1.92 μkat/L]). The patient underwent surveillance imaging with contrast-enhanced CT of the abdomen and pelvis in the venous phase ( Figure ).
Medical history and lifestyle factors have limited impact on time‐to‐first‐treatment in patients with chronic lymphocytic leukemia
Glimelius, Ingrid , Robinson, Dennis P. , Mansouri, Larry, Rostgaard, Klaus , Hjalgrim, Henrik, Hampel, Paul J. , Slager, Susan L., Smedby, Karin E. , Kleinstern, Geffen , Rabe, Kari G. , Hampel, Paul J , Rosenquist, Richard , Niemann, Carsten Utoft , Mattsson, Mattias , Parikh, Sameer A. , Rosenquist, Richard , Cerhan, James R.

Mayo Clinic

eJHaem | August 27, 2024 | Volume: 5 | Issue: 5 | Pages: 998-1004

10.1002/jha2.1000 | PMID 39415908 Get It

AbstractBackgroundChronic lymphocytic leukemia (CLL) is a heterogeneous disease. Whereas some patients have an indolent disease, others experience an aggressive course and early death. Our aim was to investigate if modifiable and non‐modifiable medical history and lifestyle factors prior to diagnosis had an impact on the natural course of the disease.MethodIn 1154 CLL patients, we assessed if the weight, physical activity, smoking, and alcohol consumption or non‐modifiable characteristics including family history of lymphoid malignancy and medical history were associated with time‐to‐first‐treatment (TTFT) and adjusted all results for the CLL‐International Prognostic Index (CLL‐IPI).ResultsTTFT was shorter for patients with high/very high‐risk CLL‐IPI than those with low/intermediate risk CLL‐IPI. In the adjusted analysis we did not find additional impact on TTFT besides CLL‐IPI from any environmental characteristics assessed.ConclusionsWe found limited impact of environmental factors on the natural course of CLL (measured as the TTFT in treatment naïve patients) providing valuable knowledge, and potential relief, to share with patients at the time of diagnosis.
Comprehensive clinical implementation, workflow, and FMEA of bespoke silicone bolus cast from 3D printed molds using open‐source resources
Hobbis, Dean , Armstrong, Michael D., Patel, Samir H. , Tegtmeier, Riley C. , Chitsazzadeh, S. , Clouser, Edward , Smetanick, Jennifer L., Pettit, Justin, Gagneur, Justin D., Stoker, J. , Buckey, C, Laughlin, Brady S. , Chitsazzadeh, Shadi, Clouser, Edward L, Stoker, Joshua B., Rong, Yi , Buckey, Courtney R, Clouser, Edward Lee , Pettit, Justin, Rong, Yi

Mayo Clinic

Journal of Applied Clinical Medical Physics | August 27, 2024 | Volume: 25 | Issue: 11 | Pages: No page available

10.1002/acm2.14498 | PMID 39189817 Get It

AbstractBackgroundBolus materials have been used for decades in radiotherapy. Most frequently, these materials are utilized to bring dose closer to the skin surface to cover superficial targets optimally. While cavity filling, such as nasal cavities, is desirable, traditional commercial bolus is lacking, requiring other solutions. Recently, investigators have worked on utilizing 3D printing technology, including commercially available solutions, which can overcome some challenges with traditional bolus.PurposeTo utilize failure modes and effects analysis (FMEA) to successfully implement a comprehensive 3D printed bolus solution to replace commercial bolus in our clinic using a series of open‐source (or free) software products.Methods3D printed molds for bespoke bolus were created by exporting the DICOM structures of the bolus designed in the treatment planning system and manipulated to create a multipart mold for 3D printing. A silicone (Ecoflex 00–30) mixture is poured into the mold and cured to form the bolus. Molds for sheet bolus of five thicknesses were also created. A comprehensive FMEA was performed to guide workflow adjustments and QA steps.ResultsThe process map identified 39 and 30 distinct steps for the bespoke and flat sheet bolus workflows, respectively. The corresponding FMEA highlighted 119 and 86 failure modes, with 69 shared between the processes. Misunderstanding of plan intent was a potential cause for most of the highest‐scoring failure modes, indicating that physics and dosimetry involvement early in the process is paramount.ConclusionFMEA informed the design and implementation of QA steps to guarantee a safe and high‐quality comprehensive implementation of silicone bolus from 3D printed molds. This approach allows for greater adaptability not afforded by traditional bolus, as well as potential dissemination to other clinics due to the open‐source nature of the workflow.
Piezo channels modulate human lung fibroblast function
Zheng, Mengning, Yao, Yang , Borkar, Niyati A. , Thompson, Michael A., Zhang, Emily , Drake, Li Y. , Ye, Xianwei , Vogel, Elizabeth R. , Pabelick, Christina M. , Prakash, Y. S. , Prakash, Y S , Drake, Li , Pabelick, Christina M , Zhang, Emily Y , Vogel, Elizabeth R , Thompson, Michael A.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | August 27, 2024 | Volume: 327 | Issue: 4 | Pages: L547-L556

10.1152/ajplung.00356.2023 | PMID 39189800 Get It

The lung is an inherently mechanosensitive organ that can respond to mechanical forces in adaptive or maladaptive ways, including via remodeling resulting in increased fibrosis. We explored the mechanisms that link mechanical forces to remodeling using human lung fibroblasts. We found that mechanosensitive Piezo channels increase with stretch and mediate extracellular matrix formation and the fibroblast-to-myofibroblast transition that occurs with stretch. Our data highlight the importance of Piezo channels in lung mechanotransduction toward remodeling.
Incidence and Predictors of Stroke in Australian Adults With Congenital Heart Disease (2000–2017)
Sodhi‐Berry, Nita , Burchill, Luke J. , Nedkoff, Lee , Katzenellenbogen, Judith , Kleinig, Timothy J , Nedkoff, Lee , Katzenellenbogen, Judith M , Burchill, Luke J , Kleinig, Timothy

Mayo Clinic

Journal of the American Heart Association | August 27, 2024 | Volume: 13 | Issue: 17 | Pages: No page available

10.1161/jaha.123.034057 | PMID 39190566 Get It

Background Adults with congenital heart disease (CHD) are at increased risk of stroke but high‐quality population level data on stroke incidence in these patients are scant. Methods and Results A retrospective whole‐population Western Australian cohort of adult patients with CHD aged 18 to 64 years was created and followed from January 2000 to December 2017 using linked hospital data. Stroke incidence rates within the adult cohort with CHD were calculated and compared with the general population via direct standardization. A nested case–control design assessed predictors of ischemic and hemorrhagic stroke within the cohort. Among 7916 adults with CHD, 249 (3.1%) incident strokes occurred at a median age of 47 years; 186 (2.3%) ischemic, 33 (0.4%) hemorrhagic and 30 (0.4%) unspecified strokes. Ischemic and hemorrhagic stroke incidence was, respectively, 9 and 3 times higher in adults with CHD than the general population. Absolute risk was low with annual rates of 0.26% (ischemic) and 0.05% (hemorrhagic). Highest rates were observed in adults with shunt and left‐sided lesions. Predictors of ischemic stroke in adults with CHD included recent cardiac surgery, left‐sided valve repair/replacements, shunt lesions, and traditional risk factors (hypertension, infective endocarditis, peripheral vascular disease, and tobacco use). Mental health disorders and increasing Charlson's comorbidity scores were strongly associated with higher risk of ischemic and hemorrhagic stroke. The CHA 2 DS 2 VASc score was associated with ischemic stroke incidence. Conclusions This study provides the first population‐based stroke incidence estimates for adults with CHD in Australia, showing elevated stroke risk across different CHD lesions. It highlights the potential clinical importance of managing comorbidities, especially mental health.
Deconvolution of the tumor-educated platelet transcriptome reveals activated platelet and inflammatory cell transcript signatures
Zhang, Ze-Yan , Ding, Yingwen , Graciani, Melanie, Sahimi, Ali , Chen, Ting , Li, Shuai , Wong, Kwok-Kin, Ramkhelawon, Bhama , Bhat, Krishna , Bhat, Krishna Pl, Karp, Jerome M. , Modrek, Aram Sandaldjian , Ezhilarasan, Ravesanker , Silvestro, Michele , Wong, Kwok‐Kin , Sulman, Erik P.

Mayo Clinic

JCI Insight | August 27, 2024 | Volume: 9 | Issue: 19 | Pages: No page available

10.1172/jci.insight.178719 | PMID 39190500 Get It

Tumor-educated platelets (TEPs) are a potential method of liquid biopsy for the diagnosis and monitoring of cancer. However, the mechanism underlying tumor education of platelets is not known, and transcripts associated with TEPs are often not tumor-associated transcripts. We demonstrated that direct tumor transfer of transcripts to circulating platelets is an unlikely source of the TEP signal. We used CDSeq, a latent Dirichlet allocation algorithm, to deconvolute the TEP signal in blood samples from patients with glioblastoma. We demonstrated that a substantial proportion of transcripts in the platelet transcriptome are derived from nonplatelet cells, and the use of this algorithm allows the removal of contaminant transcripts. Furthermore, we used the results of this algorithm to demonstrate that TEPs represent a subset of more activated platelets, which also contain transcripts normally associated with nonplatelet inflammatory cells, suggesting that these inflammatory cells, possibly in the tumor microenvironment, transfer transcripts to platelets that are then found in circulation. Our analysis suggests a useful and efficient method of processing TEP transcriptomic data to enable the isolation of a unique TEP signal associated with specific tumors.
Perioperative Management and Outcomes after Endovascular Mechanical Thrombectomy in Patients with Submassive (Intermediate-Risk) Pulmonary Embolism: A Retrospective Observational Cohort Study
Merren, Michael P. , Padkins, Mitchell , Cajigas, Héctor , Neidert, Newton B. , Abcejo, Arnoley S. , Elmadhoun, Omar, Padkins, Mitchell R , Cajigas, Hector R , Abcejo, Arnoley

Mayo Clinic

Healthcare | August 27, 2024 | Volume: 12 | Issue: 17 | Pages: 1714

10.3390/healthcare12171714 | PMID 39273738 Get It

Pulmonary embolism (PE) embodies a large healthcare burden globally and is the third leading cause of morbidity and mortality worldwide. Submassive (intermediate-risk) PE accounts for 40% of this burden. However, the optimal treatment pathway for this population remains complex and ill-defined. Catheter-directed interventions (CDIs) have shown promise in directly impacting morbidity and mortality while demonstrating a favorable success rate, safety profile, and decreased length of stay (LOS) in the intensive care unit and hospital. This retrospective review included 22 patients (50% female) with submassive PE who underwent mechanical thrombectomy (MT). A total of 45% had a contraindication to thrombolytics, the mean pulmonary embolism severity index was 127, 36% had saddle PE, the average decrease in mean pulmonary artery pressure (PAP) was 7.2 mmHg following MT, the average LOS was 6.9 days, the 30-day mortality rate was 9%, the major adverse event (MAE) rate was 9%, and the readmission rate was 13.6%. A total of 82% had successful removal of thrombus during MT with no major bleeding complications, intracranial hemorrhage events, or device-related deaths. Acknowledging the limitation of our small sample size, our data indicate that MT in the intermediate-high-risk submassive pulmonary embolism (PE) cohort resulted in a decreased hospital length of stay (LOS) and in-hospital mortality compared to standard anticoagulation therapy alone.
Full genomic sequence of the HLA‐DQB1*06:18:01 allele identified by next‐generation sequencing
Du, Zeying , Williams, C. D. H., Williams, Charles D, Du, Zeying , Williams, Charles D.

Mayo Clinic

HLA | August 27, 2024 | Volume: 104 | Issue: 2 | Pages: No page available

10.1111/tan.15664 | PMID 39189318 Get It

Full‐length sequence of HLA‐DQB1*06:18:01 covers the 5′‐untranslated region (UTR), all introns and exons, and the 3’ UTR.
Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data Set
Elmunzer, B. Joseph , Zhang, Jingwen , Coté, Gregory A. , Wani, Sachin , Shah, Raj J. , Bang, Ji Young , Varadarajulu, Shyam , Singh, Vikesh K. , Khashab, Mouen A. , Kwon, Richard S. , Scheiman, James M., Keilin, Steven , Chak, Amitabh , Slivka, Adam, Mullady, Daniel , Kushnir, Vladimir , Buxbaum, James , Keswani, Rajesh N. , Gardner, Timothy B. , Forbes, Nauzer , Rastogi, Amit, Ross, Andrew S., Law, Joanna K. , Chen, Yen‐I , Smith, Zachary L. , Petersen, Bret T. , Wang, Andrew Y. , Saltzman, John R. , Spitzer, Rebecca L., Ordiah, Collins, Spino, Cathie , Foster, Lydia D. , Durkalski‐Mauldin, Valerie, Group*, on behalf of the SVI Study, Shah, Raj , Singh, Vikesh K , Kwon, Richard S , Willingham, Field F , Chak, Amitabh , Mullady, Daniel , Forbes, Nauzer , Ross, Andrew , Law, Joanna , Chen, Yen-I , Smith, Zachary L , Serrano, Jose , Petersen, Bret, Wang, Andrew Y , Saltzman, John R , Spino, Cathie , Foster, Lydia D , Edmundowicz, Steven A. , Willingham, Field F. , Papachristou, Georgios I. , Yachimski, Patrick , Barkun, Alan , Serrano, José , Group*, on behalf of the SVI Study

Mayo Clinic

American Journal of Gastroenterology | August 27, 2024 | Volume: 120 | Issue: 4 | Pages: 811-815

10.14309/ajg.0000000000003052 | PMID 39207308 Get It

INTRODUCTION: Prophylactic pancreatic stent placement (PSP) is effective for preventing pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk cases, but the optimal technical approach to this intervention remains uncertain. METHODS: In this secondary analysis of 787 clinical trial patients who underwent successful stent placement, we studied the impact of (i) whether pancreatic wire access was achieved for the sole purpose of PSP or naturally during the conduct of the case, (ii) the amount of effort expended on PSP, (iii) stent length, (iv) stent diameter, and (v) guidewire caliber. We used logistic regression models to examine the adjusted association between each technical factor and post-ERCP pancreatitis (PEP). RESULTS: Ninety-one of the 787 patients experienced PEP. There was no clear association between PEP and whether pancreatic wire access was achieved for the sole purpose of PSP (vs occurring naturally; odds ratio [OR] 0.82, 95% confidence interval [CI] 0.37–1.84), whether substantial effort expended on stent placement (vs nonsubstantial effort; OR 1.58, 95% CI 0.73–3.45), stent length (>5 vs ≤5 cm; OR 1.01, 95% CI 0.63–1.61), stent diameter (≥5 vs <5 Fr; OR 1.13, 95% CI 0.65–1.96), or guidewire caliber (0.035 vs 0.025 in; 0.83, 95% CI 0.49–1.41). DISCUSSION: The 5 modifiable technical factors studied in this secondary analysis of large-scale randomized trial data did not appear to have a strong impact on the benefit of prophylactic PSP in preventing PEP after high-risk ERCP. Within the limitations of post hoc subgroup analysis, these findings may have important implications in procedural decision making and suggest that the benefit of PSP is robust to variations in technical approach.